| Previous Close | 29.655 |
| Open | 29.800 |
| Bid | 29.190 x 48300 |
| Ask | 29.200 x 51100 |
| Day's Range | 29.170 - 29.800 |
| 52 Week Range | 21.590 - 31.520 |
| Volume | 189,543 |
| Avg. Volume | 398,149 |
| Market Cap | 7B |
| Beta | N/A |
| PE Ratio (TTM) | 81.10 |
| EPS (TTM) | 0.36 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire•11 days ago
QIAGEN N.V. to Report Second Quarter and First Half of 2017 Results
VENLO, Netherlands, July 13, 2017 /PRNewswire/ -- QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the second quarter and first half of 2017 ...
- PR Newswire•last month
French health system approves reimbursement of QIAGEN's QuantiFERON latent TB test
Gold standard test for latent tuberculosis infection will be covered by national health insurance HILDEN , Germany , and PARIS , June 22, 2017 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime ...
- PR Newswire•2 months ago
QIAGEN's QuantiFERON®-TB Gold Plus gains U.S. FDA approval
GERMANTOWN, Md. and HILDEN, Germany, June 8, 2017 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of QuantiFERON ® -TB Gold Plus ...
